News & Events

InSysBio continues to investigate the mechanisms underlying Alzheimer’s disease (AD) using the quantitative systems pharmacology (QSP) modeling approach. The part of QSP model describing tau protein was published in the PLOS ONE journal. This is one of more than dozen InSysBio publications in AD area during last seven years.

14-16 February 2018 InSysBio held Annual Internal Scientific Meeting.

Moscow, Russia October 10, 2017 – InSysBio LLC, one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for the drug development, announced a renewal of the corporate identity.

Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.

Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.

Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.